Radium-223 dichloride is administered as an injection in the. 40 patients will take part in the study globally. Radium-223 dichloride was developed for treating metastases of prostate cancer in the bone. Radium-223 Dichloride (Ra-223) for the Treatment of Metastatic Castration-resistant Prostate Cancer: Optimizing Clinical Practice in Nuclear Medicine Center. The study will be run in several countries worldwide, and at approximately 2 hospitals in the UK. The study is sponsored by Bayer HealthCare. After this, patients will enter a long-term follow-up period and will be phoned every 6 months for up to 7 years after their last dose of radium-223 dichloride. Assessments will include blood tests, physical examinations, assessment of pain, full body bone scans, x-rays, and MRI or CT scans.Īfter the end of study treatment, the patients will enter a follow up period and continue to be evaluated for up to 2 years after their last dose of radium-223 dichloride. During the treatment phase, patients will visit the study site at least every 4 weeks for treatment and assessments. The purpose of this study is to explore the safety of re-treating patients whose prostate cancer worsened after 6 doses of radium-223 dichloride, with another 6 doses, once every 4 weeks. However, after the 6th dose, the prostate cancer in bones eventually worsens, and may cause pain and other complications. The approved way of administering radium-223 is one dose every 4 weeks for a maximum of 6 doses. The type of radiation given off (alpha particles) has a very short range (just a fraction of a millimetre) and therefore radium-223 dichloride only affects tumour cells in the bone that has taken it up. We hypothesized that alpha-emitting, bone-targeting radium 223 dichloride ( 223 RaCl 2) can be safely administered to patients with osteosarcoma and that early signals of response or resistance can be assessed by quantitative and qualitative correlative imaging studies and biomarkers. It works by giving off radioactivity which kills prostate cancer cells that have spread to bones. Radium-223 dichloride is mainly taken up into bones after it is injected. We evaluated how this change affects overall survival and the optimal timing of Ra-223 in the mCRPC treatment pathway. It is given by injection into a vein in the arm. Radium 223 dichloride is approved to treat: Prostate cancer that is castrate resistant (has not responded to treatments that lower testosterone levels). Background: Recent guidance change recommends Ra-223 following at least two prior therapies for mCRPC. Radium-223 dichloride is a radiopharmaceutical (radioactive drug) that is being investigated for the re-treatment of patients with prostate cancer that has spread to the bones.
0 Comments
Leave a Reply. |